The present invention resides in the discovery that the viral homolog of human interleukin 6 (vIL-6) originated from Kaposi's sarcoma herpesvirus (KSHV), unlike human IL-6, does not trigger negative regulatory mechanisms during an inflammatory response and therefore can be used in cancer treatment to support an unhindered anti-cancer immunity. Accordingly, this invention provides a novel method for cancer therapy by using vIL-6 to increase the immune-stimulating properties of dendritic cells, during dendritic cell production from monocytes in preparation for dendritic cell transfer therapy, as well as by co-administering vIL-6 with an anticancer therapeutic agent to achieved enhanced therapeutic immunological effects. A composition and kit for such use are also described.

The present invention relates to a peptide derived from Kaposi's sarcoma-associated herpesvirus (KSHV) vIRF3 and a use thereof. According to the present invention, the KSHV vIRF3-derived peptide inhibits the activity of PKM2, reduces the size and volume of tumors, and significantly suppresses the migration and invasion of cancer cells. Therefore, it can be advantageously utilized for the prevention, alleviation, or treatment of cancer or for inhibiting metastasis of cancer cells.

The present invention provides compositions and methods for treating a disease involving inappropriate or excessive proliferation of cells expressing CHD4.

The present invention provides compositions and methods for treating a disease involving inappropriate or excessive cell proliferation or for treating an inflammatory condition or an autoimmune disease by inhibiting MYC activity in cells such as MYC-dependent cancer cells.